CIK THERAPY FOR
COLORECTAL CANCER
Evidence, eligibility, and combination strategies for CIK cell therapy in colorectal cancer โ with a clinically important role in reducing post-surgical recurrence and extending survival alongside standard chemotherapy.
analyticsAt a Glance
- check_circleCIK therapy as post-resection adjuvant has demonstrated improved DFS and OS in stage IIโIII colorectal cancer
- check_circleCIK combined with FOLFOX chemotherapy improves tumour response and survival in advanced disease
- check_circleMicrosatellite instability (MSI) status may influence CIK combination strategy and response
- check_circleCancerFax coordinates CIK access at specialist colorectal cancer centres in China
CIK Therapy in Colorectal Cancer โ The Clinical Rationale
Colorectal cancer (CRC) is the third most common cancer globally. Despite improved surgical techniques and the addition of adjuvant chemotherapy, stage III CRC carries a 5-year recurrence risk exceeding 30%, and advanced disease remains difficult to control long-term. CIK therapy targets this recurrence risk and supplements systemic treatment through sustained immune surveillance of residual or circulating cancer cells.
โColorectal cancer recurrence is largely an immune surveillance failure โ CIK therapy is specifically designed to address this gap.โ
Adjuvant Post-Resection CIK
After curative colorectal resection (Stage IIโIII), CIK therapy administered as adjuvant immunotherapy targets micrometastatic disease in the liver, peritoneum, and lymphatic system โ improving disease-free survival in multiple randomised trials.
CIK + Chemotherapy (Advanced CRC)
In metastatic and locally advanced colorectal cancer, CIK combined with FOLFOX or XELOX regimens has shown improved overall response rate, disease control rate, and overall survival in Chinese RCTs compared to chemotherapy alone.
MSS Colorectal Cancer (Checkpoint Non-Responders)
Microsatellite-stable (MSS) CRC does not respond to PD-1/PD-L1 checkpoint inhibitors โ representing the majority of CRC patients. CIK therapy's MHC-unrestricted killing mechanism offers a potential immune approach that bypasses the MSS immune-cold tumour microenvironment.
Liver Metastasis Setting
For CRC patients with liver metastases โ the most common metastatic site โ CIK therapy has been studied alongside hepatic interventions including RFA and TACE, where the synergy between locoregional tumour destruction and immune cell infusion mirrors the liver cancer paradigm.
Clinical Efficacy Data: CIK in Colorectal Cancer
Selected outcomes from randomised controlled trials and systematic reviews of CIK therapy in colorectal cancer. Data from published Chinese academic centre studies.
Adjuvant CIK After Curative Resection โ 3-Year DFS
3-year disease-free survival in Stage IIโIII CRC patients receiving adjuvant CIK vs observation/standard adjuvant chemotherapy. Source: Chinese adjuvant CIK trials.
- 3-year DFS (adjuvant CIK)~65โ72%
- 3-year DFS (control arm)~50โ58%
CIK + FOLFOX vs FOLFOX Alone โ Advanced CRC
Tumour response and survival data from RCTs of CIK + FOLFOX/XELOX vs chemotherapy alone in locally advanced or metastatic CRC. Source: Pooled Chinese RCT data.
- ORR (CIK + FOLFOX)~48โ58%
- ORR (FOLFOX alone)~35โ44%
CIK + Chemotherapy vs Chemotherapy Alone โ 1-Year OS
1-year overall survival comparison from pooled CRC RCTs. Source: Systematic reviews of Chinese CIK colorectal cancer trials, 2013โ2023.
- 1-year OS (CIK + chemo)~75โ82%
- 1-year OS (chemo alone)~62โ70%
Colorectal Cancer Patient Eligibility for CIK Therapy
CIK therapy applies across multiple CRC treatment contexts. These parameters guide clinical assessment at specialist centres.
| Patient Factor | CIK Eligibility | Notes |
|---|---|---|
| Stage IIโIII CRC post-curative resection | โ Good evidence | Adjuvant CIK reduces recurrence โ initiate 3โ5 weeks post-surgery |
| Metastatic CRC โ first-line FOLFOX/XELOX | โ Strong evidence | Best-evidenced combination setting |
| MSS (microsatellite stable) CRC | โ Relevant | MHC-unrestricted CIK killing active regardless of MSI status |
| MSI-H CRC on checkpoint inhibitor | โ Limited data | CIK + checkpoint inhibitor combination: investigational; specialist input required |
| CRC with resectable liver metastases | โ Evidence available | CIK post-hepatic resection or post-RFA mirrors HCC paradigm |
| KRAS/BRAF mutant advanced CRC | โ No specific data | No subgroup-specific CIK data; general combination evidence applies |
| ECOG PS โฅ3 / severe nutritional depletion | โ Not appropriate | Insufficient immune reserve for effective CIK therapy |
CIK in Colorectal Cancer โ Benefits vs Limitations
A balanced clinical view of what CIK therapy contributes to colorectal cancer management and where its evidence has boundaries.
Benefits
- Active in MSS tumoursCIK's MHC-unrestricted cytotoxicity is effective regardless of microsatellite status โ filling the immune therapy gap for the ~85% of CRC patients who are MSS and checkpoint inhibitor non-responsive.
- Adjuvant recurrence reductionPost-resection adjuvant CIK demonstrably reduces 3-year relapse risk in Stage IIโIII disease โ one of the most impactful use cases across the CIK evidence base.
- No significant additive toxicityCIK infusions do not meaningfully worsen FOLFOX-associated peripheral neuropathy, nausea, or haematological toxicity in published combination trials.
- Liver metastasis synergyCIK combined with hepatic RFA or TACE for CRC liver metastases follows the same evidence logic as CIK in HCC โ locoregional destruction followed by immune cell reinforcement.
Limitations
- Chinese evidence basePublished RCT data is concentrated in China. ESMO and NCCN guidelines do not include CIK in CRC recommendations for Western practice.
- Limited MSI-H + checkpoint inhibitor dataFor the ~15% of CRC patients with MSI-H disease on pembrolizumab, the optimal role of CIK as a combination partner has not been defined.
- Multiple cycles requiredAdjuvant and combination CIK protocols typically involve 3โ6 cycles over 6โ12 months โ a sustained commitment that requires treatment planning and ongoing coordination.
- KRAS/BRAF subgroup data absentSpecific CIK evidence for KRAS-mutant or BRAF-mutant colorectal cancer subgroups does not exist โ trial populations are largely unselected by mutation status.
Colorectal Cancer and CIK โ Key Numbers
Key figures contextualising the disease burden and clinical relevance of CIK therapy in colorectal cancer.
- #3Global cancer incidence rank for colorectal cancerCRC is the third most common cancer worldwide, with increasing incidence in younger adults across Asia.
- ~85%Proportion of CRC that is MSS (checkpoint inhibitor non-responsive)The vast majority of CRC patients cannot benefit from PD-1/PD-L1 inhibitors โ making CIK a potentially important immune approach for this population.
- >30%5-year recurrence rate after curative Stage III resectionPost-surgical recurrence remains the primary driver for adjuvant CIK use in colorectal cancer.
More from the CIK Cell Therapy Resource Library
Continue exploring CIK therapy โ from the patient introduction to evidence in other cancers and combination approaches.
Frequently Asked Questions: CIK for Colorectal Cancer
Can CIK therapy replace checkpoint inhibitors for MSS colorectal cancer?
CIK therapy does not replace checkpoint inhibitors โ it fills a different clinical role. Checkpoint inhibitors (pembrolizumab, nivolumab) are highly effective in MSI-H CRC but inactive in MSS tumours. CIK therapy, through its MHC-unrestricted cytotoxicity, is active regardless of microsatellite status. For MSS patients who cannot benefit from checkpoint inhibitors, CIK represents one of the few immune-based options with a clinical evidence base โ particularly in the post-resection and chemotherapy combination settings.
Is CIK therapy relevant for rectal cancer specifically?
Yes. Although most published CIK CRC trials group colon and rectal cancers together, rectal cancer patients โ particularly those treated with neoadjuvant chemoradiotherapy followed by surgery โ represent a setting where post-treatment CIK immune reinforcement is biologically relevant. Some specialist centres in China apply CIK protocols specifically in the post-neoadjuvant, post-surgical setting for rectal cancer. Your treating oncologist would assess the timing and appropriateness for your specific case.
My colorectal cancer has spread to the liver. Can CIK still help?
For CRC patients with liver metastases, CIK therapy has been studied both as a systemic combination alongside chemotherapy and as an adjunct following hepatic RFA or resection of metastatic lesions โ mirroring the well-evidenced HCC paradigm. The immune activation triggered by locoregional liver treatment may create a more permissive environment for CIK cell activity. CancerFax can identify specialist centres in China with specific experience in this combination approach for CRC liver metastases.
How does CancerFax help CRC patients access CIK therapy in China?
We start with a complete review of your colorectal cancer records โ pathology (including MSI/MMR status, RAS/BRAF mutation profile), staging imaging, surgical reports, and current chemotherapy regimen. We prepare a structured oncology summary and identify the most appropriate specialist centre in China based on your disease profile and treatment history. We then coordinate directly with the oncology team to confirm eligibility, obtain treatment cost estimates, schedule consultations, and support travel and logistics arrangements.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Has Your Colorectal Cancer Been Treated With Surgery or Chemotherapy?
CancerFax reviews your colorectal cancer records โ staging, MSI/MMR status, RAS/BRAF profile, surgical history, and current treatment โ and identifies whether CIK therapy as adjuvant or combination treatment is appropriate for your case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.